Proveca
Develops and licenses medicines for children with unmet needs in neurology and cardiology
Highlights
- New on EvolcAdded 2026-10-27
About Proveca
Proveca develops and licenses medicines for paediatric use, including treatments in neurology and cardiology. Its work includes identifying, developing and licensing off-patent medicines for children's unmet healthcare needs.
The company provides medicines to healthcare markets internationally and works with clinicians, parents, carers and children. Its products include Sialanar (glycopyrronium bromide) and Aqumeldi (enalapril maleate).
Proveca was founded in 2010 and is headquartered in Manchester, UK. It also presents an Irish entity in Dublin.
Product: Development and licensing of paediatric medicines, including Sialanar and Aqumeldi.
Jobs at Proveca
Leadership
- Helen Shaw · Founder, DirectorSource: company website
- Simon Bryson · Founder, Chief Executive OfficerSource: company website
- Andrew Jackson · Chief Financial OfficerSource: company website
More biotech & pharma companies
Psivac
Develops oncolytic adenovirus therapies for cancer patients, targeting solid tumoursNew on EvolcQuantumdx Group
Point-of-care molecular diagnostic platforms and assays for clinicians and healthcare providersNew on EvolcReach Separations
Chromatography analysis and purification services for pharmaceutical, agrochemical and fine chemical companiesNew on EvolcSalary transparentRedx Pharma
Clinical-stage biotech developing small-molecule anti-fibrotic drugs, led by a ROCK inhibitor for Crohn's diseaseNew on EvolcRefeyn
Mass photometry instruments and consumables for protein, antibody and viral vector analysis in research and biopharma labsSalary transparentrelationrx
AI-enabled drug discovery and development for pharmaceutical partners and patients
Website technologies
Older, unverified list. Detection dates and supporting evidence are not yet available.
- Cloudflare
- Google Tag Manager
- LiteSpeed
- PHP
- WordPress
- jQuery